InMed Pharmaceuticals is a pre-clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems.

InMed is utilizing its proprietary bioinformatics assessment tool to dentify  cannabinoid  compounds, or combinations thereof, that have therapeutic potential in diseases with high  unmet medical needs. The goal is to identify new drug candidates that optimize therapeutic benefit while limiting adverse effects.

InMed’s proprietary in silico drug/disease bioinformatics assessment tool,  cannabinoid  biosynthesis technology and drug development pipeline are the fundamental value drivers of the Company.